Endovascular Lower Extremity Interventions

Are the Reported Advantages of Pacitaxil Therapy worth the potential risks?

Darren Schneider, MD | 2020 Annual Meeting

Paclitaxel: Friend or Foe…Data Driven Decision Making (Sponsored by Boston Scientific)

Michael Jaff, DO | 2020 Annual Meeting

Propensity-Matched Analysis of Patients Treated with Paclitaxel-Coated Versus Uncoated Balloons

Alexander King, MS | 2020 Annual Meeting

A Real World Experience of Drug Eluting and Non-drug Eluting Stents In Lower Extremity Peripheral Arterial Disease

Pavel Kibrik, MD | 2018 Annual Meeting

Influence of Heel Ulceration on Limb Salvage after Open and Endovascular Intervention for Limb Threatening Critical Ischemia

Mark G. Davies, MD | 2018 Annual Meeting

Drug Coated Balloon Angioplasty Confers No Advantage In The Treatment Of Femoropopliteal Disease When Stenting Is Required

Kathleen Ozsvath, MD | 2018 Annual Meeting

Coronary Drug-Eluting Stents for the Treatment of Threatened LowerExtremity Bypass Grafts: a Single Institution Case Series

Jon Quatromoni, MD | 2018 Annual Meeting

The Impact on Wound Healing and Major Amputation Free Survivalin Patients with Isolated Below the Knee Arterial Disease Following Angiosome Directed Endovascular Revascularization

Elliott Walters, MD | 2018 Annual Meeting

Effects of Endovascular First Strategy on Splice Vein Bypass Outcomes

Andre Ramdon, MD | 2018 Annual Meeting

Nationwide Trends in Drug-Coated Balloon and Drug-Eluting Stent Utilization in the Femoropopliteal Arteries

Abhisekh Mohapatra, MD | 2018 Annual Meeting